BioSpace Collaborative

Academic/Biomedical Research
News & Jobs
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

PROFILES
Company Profiles

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Research Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
Get Our Industry eNewsletter FREE email:    
   

Roche (RHHBY)'s Avastin Strikes Out Again With National Institute for Clinical Excellence (NICE)


8/22/2012 6:45:35 AM

NICE has now issued final guidance saying it does not recommend Avastin (bevacizumab), in combination with Roche’s Xeloda, for the firstline treatment of metastatic breast cancer in people for whom treatment with other chemotherapy options including taxanes or anthracyclines, is not considered appropriate. The watchdog says its recommendation has remained constant throughout the process of guidance development - i.e., not recommending the treatment - adding that neither Roche nor other consultees had raised objections to NICE at any stage. Sir Andrew Dillon, NICE’s chief executive, said: “We can’t recommend a drug that has not been shown to work as well as, or better than, current treatments and costs much more.

Read at InPharm.com
Read at News Release
Read at The Independent

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES
 

//-->